P124: Tissue Factor and Protease-Activated Receptor 2 associated genes are upregulated in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Qiu, Y.(1);Yao, L.(1);Taylor Meadows, K.(1);Rey, D.(1);Khalid, M.(2)*;Travis, S.(3);
(1)Endpoint Health, Research, Palo Alto, United States;(2)Endpoint Health, Portfolio Strategy & Scientific Affairs, London, United Kingdom;(3)National Institute for Health and Care Research Oxford Biomedical Research Centre- University of Oxford, Translational Gastroenterology Unit and Kennedy Institute, Oxford, United Kingdom;
P125: MIG (CXCL9) and IL22 are key biomarkers that discriminates between paediatric IBD patients and non-IBD patients in a novel biomarker modelECCO'24Year: 2024
Authors: Eindor, A.(1)*;Tsai, K.(2);Jacobson, K.(3);
(1)Shamir medical center affiliated to Tel Aviv university, Division of Gastroenterology- Hepatology and Nutrition, Tel Aviv, Israel;(2)BC children@E@s hospital research institute, Pediatric Gastroenterology- Hepatology and Nurtition, Vancouver, Canada;(3)BC Children@E@s hospital, Pediatric Gastroenterology- Hepatology and Nutrition, Vancouver, Canada;
P126: Differential granulocyte populations as therapeutic targets in fistulaECCO'24Year: 2024
Authors: Becker, M.(1);Koelink, P.(2);Buskens, C.(3);Wildenberg, M.(4)*;
(1)Amsterdam UMC- Tytgat Institute, Gastroenterology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Tytgat Institute, Amsterdam, The Netherlands;(3)Amsterdam UMC, Surgery, Amsterdam, The Netherlands;(4)Academic Medical Center AMC Tytgat Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P127: Sphingosine-1-Phosphate Receptor Blockade with Etrasimod alters Lymphocyte Trafficking in Crohn@E@s Disease: Insights from High-Dimensional Phenotypic Mapping.ECCO'24Year: 2024
Authors: Nikolakis, D.(1)*;Pruijt, M.J.(2);Aberkrom, V.E.R.(2);de Voogd, F.A.E.(2);Branquinho, D.(3);Crosby, C.(4);Teichert, C.(2);van de Sande, M.G.H.(5);Grootjans, J.(2);D@E@Haens, G.R.A.M.(2);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology- Amsterdam Institute for Gastroenterology Endocrinology and Metabolism / Department of Rheumatology & Clinical Immunology- Amsterdam Institute for Infection & Immunity, 1105 AZ Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Gastroenterology and Hepatology- Amsterdam Institute for Gastroenterology Endocrinology and Metabolism, 1105 AZ Amsterdam, The Netherlands;(3)Pfizer, Inc, New York NY, United States;(4)Pfizer, Inc, San Diego CA, United States;(5)Amsterdam UMC, Department of Rheumatology & Clinical Immunology- Amsterdam Institute for Infection & Immunity- Amsterdam Rheumatology & Immunology Center ARC, 1105 AZ Amsterdam, The Netherlands;
P128: Salt-Inducible Kinase 2 is a promising therapeutic target in patients with ulcerative colitisECCO'24Year: 2024
Authors: McMillan, L.(1);Felwick, R.(2)*;Barbeta, G.(3);Fenton-May, A.(1);Kelly, M.(1);Strickland, M.(1);Richmond, N.(1);Bennett, N.(1);Makrecka-Kuka, M.(1);Sanchez-Elsner, T.(3);Cummings, F.(2);Madden , J.(1);Kilty, I.(1);
(1)Sitryx Therapeutics, Sitryx Therapeutics, Oxford, United Kingdom;(2)University Hospital Southampton, Gastroenterology, Southampton, United Kingdom;(3)University of Southampton, Clinical and Experimental Sciences, Southampton, United Kingdom;
P129: Anastomotic healing is functionally not impaired after ileocecal resection in a mouse model of Crohn@E@s-like ileitisECCO'24Year: 2024
Authors: Berlin, P.(1)*;Fischer, A.(1);Reiner, J.(1);Schafmeyer, C.(2);Lamprecht, G.(1);Witte, M.(2);
(1)University Medical Center Rostock, Division of Gastroenterology, Rostock, Germany;(2)University Medical Center Rostock, Department of General- Visceral- Thoracic- Vascular and Transplant Surgery, Rostock, Germany;
P130: High serum lipocalin-2 expression at the diagnosis in children with ulcerative colitis: a pilot studyECCO'24Year: 2024
Authors: D@E@Arcangelo, G.(1)*;Petrella, C.(2);Zucconi, F.(1);Fiore, M.(2);Distante, M.(1);Aloi, M.(1);
(1)Sapienza University of Rome, Department of Pediatrics, Rome, Italy;(2)Institute of Biochemistry and Cell Biology, Department of Sensory Organs- Sapienza University of Rome, Rome, Italy;
P132: Overexpression of miR-376a-3p in exosomes circulating in peripheral blood of patients with Crohn@E@s disease.ECCO'24Year: 2024
Authors: Caparrós, E.(1);García, I.(2);Madero Velázquez, L.(3);Mira, C.(4);Martínez, A.(2);Gutiérrez Casbas, A.(5)*;Francés, R.(1,6);
(1)Universidad Miguel Hernández, Immunology, San Juan de Alicante, Spain;(2)Instituto Severo Ochoa, Immunology, Madrid, Spain;(3)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Gastroenterology, Alicante, Spain;(4)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology, Alicante, Spain;(5)Hospital General Universitario Alicante, Gastroenterology- CIBERehd- Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Alicante, Spain;(6)CIBERehd, Immunology, Madrid, Spain;
P133: In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimensECCO'24Year: 2024
Authors: Hettema, W.(1);Nolain, P.(2);Parent, I.(3);Blanqué, R.(3);Furio, L.(4);Lagoutte, E.(4);Angella, L.(4);Dao, J.(5);Galien, R.(6)*;
(1)Galapagos B.V., Clinical Pharmacology, Leiden, The Netherlands;(2)Galapagos SASU, Pharmacometrics, Romainville, France;(3)Galapagos SASU, Translational Science, Romainville, France;(4)Galapagos SASU, Translational Science Biomarkers, Romainville, France;(5)Galapagos SASU, Clinical Pharmacology, Romainville, France;(6)Galapagos SASU, Department of Inflammation, Romainville, France;
P134: Characterization for the similarity assessment between proposed biosimilar SB17 and ustekinumab reference product using state-of-the-art analytical methodECCO'24Year: 2024
Authors: Yang, S.Y.(1)*;Lee, C.(1);Hwang, K.(1);Lee, J.(1);Lee, J.(1);Hong, J.(1);Jung, S.(1);
(1)Samsung Bioepis Co.- Ltd, Quality Evaluation Team, Incheon, Korea- Republic Of;
P135: Mixed probiotics containing Bifidobacterium longum and its metabolites inhibit the formation of NLRP3 inflammasomes by suppressing GBP5 expression in macrophages in ulcerative colitisECCO'24Year: 2024
Authors: Zhou, H.(1)*;Wu, T.(1);Wang, F.(1);Zhang, T.(1);Lin, J.(1);Shi, Y.(1);Liang, J.(1);
(1)Fourth Military Medical University, Xijing Hospital of Digestive Diseases, Xi@E@an, China;
P136: Blood-based biomarkers of type III collagen remodeling as surrogate markers of endoscopic disease activity in patients with Ulcerative Colitis.ECCO'24Year: 2024
Authors: Pehrsson, M.(1)*;Poulsen, A.(2);Alexdottir, M.S.(1);Seidelin, J.B.(3);Mortensen, J.H.(1);
(1)Nordic Bioscience A/S, Biomarkers and Research, Herlev, Denmark;(2)Bispebjerg Hospital- University of Copenhagen, Digestive Disease Center, Copenhagen, Denmark;(3)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;
P137: Salivary calprotectin: a potential biomarker in inflammatory bowel disease?ECCO'24Year: 2024
Authors: Rodrigues, C.(1)*;Gomes, A.(2);Leal, J.(3);Mendes, K.(2);Correia, M.J.(2);Pereira, P.(2);Martins, R.(2);Nélio, V.(2);Rosa, N.(2); Soares, C.(4);Ministro, P.(4);
(1)Centro Hospitalar Tondela-Viseu- Viseu- Portugal, Gastroenterology Department, Viseu, Portugal;(2)Universidade Católica Portuguesa- Faculty of Dental Medicine, Center for Interdisciplinary Research in Health, Viseu, Portugal;(3)Centro Hospitalar Tondela-Viseu, Clinical Pathology Department, Viseu, Portugal;(4)Centro Hospitalar Tondela-Viseu- Viseu, Gastroenterology Department, Viseu, Portugal;
P138: Novel serum markers for predicting disease activity in ulcerative colitis: results from a retrospective case-control studyECCO'24Year: 2024
Authors: State, R.M.(1)*;Popp, C.(2);Balanescu, P.(3);Voiosu, A.(1);Coman, A.(2);Bengus, A.(1);Negreanu, L.(4);Mateescu, R.B.(1);Voiosu, T.(1);
(1)Colentina Clinical Hospital, Gastroenterology Department, Bucharest, Romania;(2)Colentina Clinical Hospital, Pathology, Bucharest, Romania;(3)Carol Davila University of Medicine and Pharmacy- Bucharest- Romania, Internal Medicine, Bucharest, Romania;(4)University Emergency Hospital Bucharest, Gastroenterology Department, Bucharest, Romania;
P139: A potential protective rule of Mannose Binding lectin (MBL) against SARS-COV2 infection in IBD patientsECCO'24Year: 2024
Authors: Albertini, G.(1)*;Pisani, L.F.(2);Bolzoni, A.(3);Annunziata, M.L.(1);Porta, C.(4);Pastorelli, L.(5);
(1)IRCCS Policlinico San Donato, Gastroenterology and Digestive Endoscopy, Milan, Italy;(2)Centro Cardiologico Monzino IRCCS, Immunology and Functional Genomics Unit, Milan, Italy;(3)Università degli Studi di Milano, Department of Health Sciences, Milan, Italy;(4)University of Piemonte Orientale, Center for Translational Research on Autoimmune and Allergic Diseases, Novara, Italy;(5)ASST Santi Paolo e Carlo, Gastroenterology and Liver Unit, Milan, Italy;
P140: Serum Metabolomic Biomarkers Can Identify and Characterize Associated Subtypes and Phenotypes in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Kim, J.(1)*;Suh, D.H.(2);Park, Y.J.(2);Oh, S.J.(1);Kang, H.(2);Ji, Y.(2);Jung, E.S.(2);Lee, C.K.(1);
(1)Kyung Hee University College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;(2)HEM Pharma Inc, Multi-Omics Center, Suwon- Gyeonggi, Korea- Republic Of;
P142: Genetic ablation of DNA methyltransferase 3A in myeloid cells impairs M1/M2 polarization and leads to pro-inflammatory macrophagesECCO'24Year: 2024
Authors: Bordoni, D.(1);Escudero-Hernández, C.(1)*;Kimmig, F.(1);Mishra, N.(1);Fazio, A.(1);Tran, F.(1);Imm, S.(1);Hinrichsen, F.(1);Weber-Stiehl, S.(1);Stengel, S.(1);Sommer, F.(1);Falk-Paulsen, M.(1);Rosenstiel, P.(1);
(1)University Hospital Schleswig-Holstein and Christian-Albrechts-University Kiel, Institute of Clinical Molecular Biology IKMB, Kiel, Germany;
P143: Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitisECCO'24Year: 2024
Authors: Kong, K.F.(1)*;Khan, M.A.W.(1);Singh, N.(2);Nguyen, V.A.(3);Wilson, E.(1);Tang, J.(1);Marusic, S.(4);Xia, G.(1);Petrakis, I.(5);Nguyen, D.G.(1);
(1)Takeda Development Center Americas- Inc., Gastroenterology Drug Discovery Unit, Lexington- MA, United States;(2)Takeda Development Center Americas- Inc., Clinical Sciences, Lexington- MA, United States;(3)Takeda Development Center Americas- Inc., Quantitative Clinical Pharmacology, Lexington- MA, United States;(4)Hooke Laboratories, President, Lawrence- MA, United States;(5)Takeda Development Center Americas- Inc., Gastroenterology Therapeutic Area Unit, Lexington- MA, United States;
